aTyr Pharma (ATYR) vs BioCardia (BCDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
BioCardia (BCDA) has outperformed aTyr Pharma (ATYR) over the past year, losing 25.2% versus a loss of 74.2%. Over five years, ATYR leads with a -97.2% price change compared with -97.6% for BCDA. aTyr Pharma is the larger company by market cap ($24.1 million vs $15.7 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | BCDA |
|---|---|---|
| Share price | $0.2462 | $1.04 |
| Market cap | $24.15M | $15.74M |
| 1-day change | -3.56% | -1.89% |
| YTD return | -68.56% | -16.80% |
| 1-year return | -74.17% | -25.18% |
| 5-year return | -97.17% | -97.59% |
| EPS (TTM) | $-0.59 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.11 | $1.80 |
| 52-week low | $0.246 | $0.75 |
| Distance from 52-week high | -77.82% | -42.22% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1061.66% | +1390.38% |
| Average volume | 3.27M | 282.05K |
| Shares outstanding | 98.09M | 15.14M |
| Employees | 58 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed ATYR by 49.0 percentage points over the past year.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
ATYR vs BCDA FAQ
Which is bigger, aTyr Pharma or BioCardia?
aTyr Pharma (ATYR) is larger, with a market capitalization of $24.15M compared with $15.74M for BioCardia (BCDA).
Which stock has performed better over the past year, ATYR or BCDA?
BCDA returned -25.18% over the past 12 months, compared with -74.17% for ATYR (price return, excluding dividends). Past performance does not predict future results.
Are aTyr Pharma and BioCardia in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.